19 results
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... (ER version) ... Ozempic), or daily tablet ... side effects (e.g ... Receptor #Agonists #Pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... Penicillium marneffei Infections ... amphotericin B, 3 to 5 mg/kg ... Penicilliosis #IDSA ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
IDSA Recommendations ... ., 4 mg/kg on days ... dose of 20–60 mg/kg ... opportunistic #infections ... #HIVAIDS #pharmacology
Coverage of common antibiotics used in the hospital

For empiric coverage, first define the type of infection,
define the type of infection ... prior resistance. e.g ... #antibiogram #pharmacology ... #table #sensitivities
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... mucoadhesive buccal tablet ... chew, or crush tablet ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
IDSA Recommendations ... Nifurtimox 8–10 mg/kg ... Trypanosomiasis #IDSA ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Guidelines - Table ... Clostridium difficile infection ... Episode #Pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
IDSA Recommendations ... amphotericin B 3–5 mg/kg ... deoxycholate 0.7–1.0 mg/kg ... Coccidiodomycosis #IDSA ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... Cytomegalovirus Infections ... other factors (e.g ... Cytomegalovirus #CMV #IDSA ... #HIVAIDS #pharmacology
IDSA - Diabetic Foot Infections - Suggested Route, Setting, and Duration of Antibiotic Therapy, by Clinical
IDSA - Diabetic ... Foot Infections ... infected tissue (eg ... Diabetic #Foot #Infections ... #antibiotics #pharmacology